AbbVie has acquired Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T) for $5.8 billion. Rova-T is currently in registrational trials for small cell lung cancer (SCLC) and according to the company is a novel biomarker-specific therapy that is derived from cancer stem cells and targets delta-like protein 3 (DLL3) that is expressed in more than 80 percent of SCLC patient tumors and is not present in healthy tissue. Registrational trials for third-line small cell lung cancer ...